Sandbox: ay: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(15 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Pathophysiology==
==Historical prespective==
===Vaginal Defensive mechanisms aganist Candida===
====Innate Mechanisms====
{| class="wikitable"
!Defense
!Mechanism of protection
!Evidence of protection
|-
|Vaginal [[epithelial cells]]
|
*[[In vitro]] inhibition of [[Candida]] growth<ref name="pmid16239581">{{cite journal| author=Barousse MM, Espinosa T, Dunlap K, Fidel PL| title=Vaginal epithelial cell anti-Candida albicans activity is associated with protection against symptomatic vaginal candidiasis. | journal=Infect Immun | year= 2005 | volume= 73 | issue= 11 | pages= 7765-7 | pmid=16239581 | doi=10.1128/IAI.73.11.7765-7767.2005 | pmc=1273905 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16239581  }}</ref>
|
*Protective role [[in vivo]] unknown
*Patients with recurrent [[candida]] infections have decreased anti-Candida activity
|-
|Mannose-binding lectin
|
*[[Epithelial cell]] associated [[protein]] which binds to [[Candida]] surface mannan.<ref name="pmid18715406" />
*Inhibits [[Candida]] growth by activating [[complement]]<ref name="pmid15243942">{{cite journal| author=Ip WK, Lau YL| title=Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in [[phagocytosis]] by human dendritic cells. | journal=J Infect Dis | year= 2004 | volume= 190 | issue= 3 | pages= 632-40 | pmid=15243942 | doi=10.1086/422397 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15243942  }}</ref>
*Activity is genetically determined
|
*Decreased expression can increase the susceptibility for [[vaginal colonization]] of [[candida]] and leading to [[vaginitis]]
|-
|Activated [[lactoferrin]]<ref name="pmid15603095">{{cite journal| author=Naidu AS, Chen J, Martinez C, Tulpinski J, Pal BK, Fowler RS| title=Activated lactoferrin's ability to inhibit Candida growth and block yeast adhesion to the vaginal epithelial monolayer. | journal=J Reprod Med | year= 2004 | volume= 49 | issue= 11 | pages= 859-66 | pmid=15603095 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15603095  }}</ref>
|
*Fungistatic and fungicidal activity
|
*Role in protection aganist infection is not clear
|-
|Vaginal [[bacterial flora]]
|
*[[Lactobacillus]] species compete for nutrients.
*[[Bacteriocins]] and [[hydrogen peroxide]] inhibit yeast growth/[[germination]]
|
*Role in protection aganist vaginitis still unclear
|-
|Phagocytic systems/polymononuclear [[leukocytes]], [[mononuclear cells]], [[complement]]
|
*Mainly found in [[lamina propria]] in experimental vaginitis, help in reducing the [[yeast]] load and its invasion by [[phagocytosis]] and intracellular killing<ref name="pmid340470">{{cite journal| author=Diamond RD, Krzesicki R, Jao W| title=Damage to pseudohyphal forms of Candida albicans by neutrophils in the absence of serum in vitro. | journal=J Clin Invest | year= 1978 | volume= 61 | issue= 2 | pages= 349-59 | pmid=340470 | doi=10.1172/JCI108945 | pmc=372545 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=340470  }}</ref>
*[[Nitric oxide]] has anti-Candida activity
|
*Role in protection still unclear
|}


====Adaptive Mechanisms====
B. Lagenbeck in 1839 in Germany was the first to demonstrate that a yeast-like fungus existed in the human oral infection "thrush." He also found that a fungus was able to cause thrush.<ref name="pmid18509848">{{cite journal |vauthors=Barnett JA |title=A history of research on yeasts 12: medical yeasts part 1, Candida albicans |journal=Yeast |volume=25 |issue=6 |pages=385–417 |year=2008 |pmid=18509848 |doi=10.1002/yea.1595 |url=}}</ref>
{| class="wikitable"
!Defense
!Mechanism
!Role in Protection
|-
|[[Immunoglobulin]] mediated [[immunity]]
|Systemic [[IgM]], [[IgG]], and local [[IgA]] antibodies are produced in response to the infection<ref name="pmid4556009">{{cite journal| author=Waldman RH, Cruz JM, Rowe DS| title=Immunoglobulin levels and antibody to Candida albicans in human cervicovaginal secretions. | journal=Clin Exp Immunol | year= 1972 | volume= 10 | issue= 3 | pages= 427-34 | pmid=4556009 | doi= | pmc=1713147 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4556009  }}</ref>


|
The genera ''Candida'', species ''albicans'' was described by botanist Christine Marie Berkhout. She described the fungus in her doctoral thesis, at the University of Utrecht in 1923. Over the years the classification of the genera and species has evolved. Obsolete names for this genus include ''Mycotorula'' and ''Torulopsis''. The species has also been known in the past as ''Monilia albicans'' and ''Oidium albicans''. The current classification is ''nomen conservandum'', which means the name is authorized for use by the [http://www.bgbm.org/iapt/nomenclature/code/SaintLouis/0000St.Luistitle.htm International Botanical Congress (IBC)].  
*Protective role not proven.
*Elevated [[titres]] of vaginal anti-Candida [[IgG]], [[IgA]] are detected in women with recurrent vaginitis
*Persistent symptoms could be attributed to anti-Candida [[IgE]]<ref name="pmid8809464">{{cite journal| author=Fidel PL, Sobel JD| title=Immunopathogenesis of recurrent vulvovaginal candidiasis. | journal=Clin Microbiol Rev | year= 1996 | volume= 9 | issue= 3 | pages= 335-48 | pmid=8809464 | doi= | pmc=172897 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8809464  }}</ref>
|-
|[[Cell Mediated Immunity]]
|
[[Interleukin 4]] (Th2) inhibits anti-Candida activity of [[nitric oxide]] and protective pro-inflammatory Th1 [[cytokines]].<ref name="pmid15735412">{{cite journal| author=Fidel PL| title=Immunity in vaginal candidiasis. | journal=Curr Opin Infect Dis | year= 2005 | volume= 18 | issue= 2 | pages= 107-11 | pmid=15735412 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735412  }}</ref>
|
*Role in protection from [[vulvovaginitis]] is still not clear
*It is still a hypothesis<ref name="pmid15102806">{{cite journal| author=Fidel PL, Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin DH et al.| title=An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. | journal=Infect Immun | year= 2004 | volume= 72 | issue= 5 | pages= 2939-46 | pmid=15102806 | doi= | pmc=387876 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15102806  }}</ref>
*Patients with recurrent infection have undetectable Th2 [[cytokines]].
|}


===Candida Virulence Factors===
The full current taxonomic classification is available at ''[[Candida albicans]]''.
*[[C. albicans]] exists as [[blastospores]], [[germ tubes]], [[pseudomycelia]], [[true mycelia]] and [[chlamydospores]] on special [[culture]] media. [[C. glabrata]] exists exclusively in [[blastospores]].
*All strains of [[Candida]] species possess a [[yeast]] surface [[mannoprotein]] which helps in adhering to [[epithelial cells]] of the [[vagina]].<ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref><ref name="pmid3895958">{{cite journal |vauthors=Sobel JD |title=Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis |journal=Am. J. Obstet. Gynecol. |volume=152 |issue=7 Pt 2 |pages=924–35 |year=1985 |pmid=3895958 |doi= |url=}}</ref>
*[[Germination]] of the spores helps in colonizing the vagina.<ref name="pmid6327527">{{cite journal| author=Sobel JD, Muller G, Buckley HR| title=Critical role of germ tube formation in the pathogenesis of candidal vaginitis. | journal=Infect Immun | year= 1984 | volume= 44 | issue= 3 | pages= 576-80 | pmid=6327527 | doi= | pmc=263631 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6327527  }} </ref>
*Proteolytic enzymes, toxins and [[phospholipase]] destroy the [[proteins]] that normally impair [[fungal]] invasion, enhancing the ability of [[Candida]] to colonize the [[vagina]].<ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref><ref name="pmid3895958">{{cite journal |vauthors=Sobel JD |title=Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis |journal=Am. J. Obstet. Gynecol. |volume=152 |issue=7 Pt 2 |pages=924–35 |year=1985 |pmid=3895958 |doi= |url=}}</ref><ref name="pmid2688924">{{cite journal |vauthors=Sobel JD |title=Pathogenesis of Candida vulvovaginitis |journal=Curr Top Med Mycol |volume=3 |issue= |pages=86–108 |year=1989 |pmid=2688924 |doi= |url=}}</ref><ref name="pmid12761103">{{cite journal| author=Schaller M, Bein M, Korting HC, Baur S, Hamm G, Monod M et al.| title=The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. | journal=Infect Immun | year= 2003 | volume= 71 | issue= 6 | pages= 3227-34 | pmid=12761103 | doi= | pmc=155757 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12761103  }}</ref>
*[[Phenotypic switching]] of [[Candida]] is described in patients with recurrent vaginitis.<ref name="pmid3284370">{{cite journal| author=Soll DR| title=High-frequency switching in Candida albicans and its relations to vaginal candidiasis. | journal=Am J Obstet Gynecol | year= 1988 | volume= 158 | issue= 4 | pages= 997-1001 | pmid=3284370 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3284370  }}</ref>
*[[C. albicans]] can form [[biofilm]]s on the [[intrauterine devices]] or sponges, causing disease recurrence.<ref name="pmid25935553">{{cite journal| author=Muzny CA, Schwebke JR| title=Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. | journal=Clin Infect Dis | year= 2015 | volume= 61 | issue= 4 | pages= 601-6 | pmid=25935553 | doi=10.1093/cid/civ353 | pmc=4607736 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25935553  }}</ref>


===Pathogenesis===
The genus ''Candida'' includes about 150 different species. However, only a few of those are known to cause human infections. ''C. albicans'' is the most significant pathogenic (=disease-causing) species. Other ''Candida'' species causing diseases in humans include ''C. tropicalis'', ''C. glabrata'', ''C. krusei'', ''C. parapsilosis'', ''C. dubliniensis'', and ''C. lusitaniae''.
*[[Candida (genus)|Candida]] vulvovaginitis is a microbial disease and not all patients with detectable pathogen are symptomatic. Multiple [[risk factors]] and the imbalance in the protective vaginal defenses predispose patients to develop active disease.
 
*[[Candida]] vaginal infections are more common in the reproductive age group because of the high concentration of [[estrogen]] as it increases the amount of [[glycogen]] in the [[vagina]] providing a carbon source for [[Candida]] organisms to [[colonize]]. It also increases the adherence of [[Candida]] to the [[vaginal epithelial cells]].<ref name="pmid11592551">{{cite journal| author=Dennerstein GJ, Ellis DH| title=Oestrogen, glycogen and vaginal candidiasis. | journal=Aust N Z J Obstet Gynaecol | year= 2001 | volume= 41 | issue= 3 | pages= 326-8 | pmid=11592551 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11592551  }}</ref>
 
*The most common source of the infection is from the [[perianal]] area. Other less common source is [[sexual transmission]] and persistence of organisms in the [[vagina]] after treatment which is responsible for recurrence.<ref name="pmid333134">{{cite journal| author=Miles MR, Olsen L, Rogers A| title=Recurrent vaginal candidiasis. Importance of an intestinal reservoir. | journal=JAMA | year= 1977 | volume= 238 | issue= 17 | pages= 1836-7 | pmid=333134 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=333134 }}</ref>
==Classification:<ref name="urlCandidiasis | Types of Diseses | Fungal Diseases | CDC">{{cite web |url=https://www.cdc.gov/fungal/diseases/candidiasis/ |title=Candidiasis &#124; Types of Diseses &#124; Fungal Diseases &#124; CDC |format= |work= |accessdate=}}</ref>==
*The initial step of infection is [[colonization]] and symptoms appear with the invasion of the [[blastospores]] or [[pseudohyphae]] of the [[vaginal wall]].<ref name="pmid9880475">{{cite journal| author=Fidel PL, Vazquez JA, Sobel JD| title=Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. | journal=Clin Microbiol Rev | year= 1999 | volume= 12 | issue= 1 | pages= 80-96 | pmid=9880475 | doi= | pmc=88907 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9880475 }}</ref>
Candidiasis can be classified according to the site of infection into:
*The understanding of the transition from asymptomatic vaginal colonization with [[Candida]] to symptomatic [[vulvovaginitis]] is not clear.<ref name="pmid3895958">{{cite journal |vauthors=Sobel JD |title=Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis |journal=Am. J. Obstet. Gynecol. |volume=152 |issue=7 Pt 2 |pages=924–35 |year=1985 |pmid=3895958 |doi= |url=}}</ref><ref name="pmid2688924">{{cite journal |vauthors=Sobel JD |title=Pathogenesis of Candida vulvovaginitis |journal=Curr Top Med Mycol |volume=3 |issue= |pages=86–108 |year=1989 |pmid=2688924 |doi= |url=}}</ref>
 
===Localoized mucocutaneous:===
 
*Oropharyngeal candidiasis
*Esophageal candidiasis
*Candida vulvovaginitis
*Chronic mucocutaneous candidiasis.
 
====Invasive Candidiasis:====
More serious and usually presenting in an immunocompromised host.
 
*Candidaemia
*Candida endophthalmitis
*Candida endocarditis
*Candida osteoarticular disease
 
==Pathophysiology:==
Candida is a normal commensal of skin and mucous membranes. A competent immune system and an intact regenerating healthy skin prevent the virulence of Candida.
 
The main virulence factors that mediate the infection: (2)
#Secreting '''molecules that mediate adherence''' into host cells
#Production of '''hydrolases''' which has a lytic effect on tissues and facilitate the invasion by the bacteria.
#'''Polymorphism:''' Candida has the ability to grow either as pseudohyphae (elongated elipsoid form) or in a yeast form (rounded to oval budding form. While the role of #polymorphism is not clearly understood in the virulence of Candida, it’s noted that species capable of producing the most severe form of the disease has this ability.
#'''Biofilm production:''' which means the ability to form a thick layer of the organism on the mucosal surfaces or even on catheters and dentures.
 
Patients was candida vulvovaginitis were found to have decreased levels of mannose binding lectins (MBL) . Further investigations revealed that 2 genetic mutations in genes responsible for MBL and IL4 production increase the host susceotibility of getting recurrent candidal vulvovaginitis.(3)
 
==Risk factors:==
Any condition that compromises cell mediated immunity, worsens the general status of the patient or provide a favorable medium for candida to form biofilms  put the patient at increased risk for having candidiasis.(4)
 
===Conditions that compromises cell mediated immunity:===
*T cell deficiencies as in DiGeorge syndrome, Wiscot-Aldrich syndrome and ataxia-telengictasia.
*Bone marrow transplant
*Leukaemias
*Corticosteroids use or immunosuppresive drugs.
 
===Conditions that worsens the general condition:===
*Malignancies
*Recent chemotherapy
*Trauma
*Recent surgery
*Prolonged hospitalization
*Broad spectrum antibiotics
*Renal failure
*Haemodialysis (especially if prolonged)
 
===Dentures that provide a favorable media for forming biofilms:===
*Prolonged central venous catheters insertion
*Prolonged foley’s catheter insertion
*Prolonged mechanical ventilation
 
==Clinical manifaestations:==
 
Oropharyngeal candidiasis:(5), (6)
   
Many cases are asymptomatic (mild disease or poor general condition)
Dysphagia or odynphagia
Difficulty tasting food
feeling of mouth fullness and discomfort
Candida esophagitis:(7)
Candida esophagitis usually comes late in the course of AIDS (or any immunodeficiency) (8), so patient has the symptoms and signs of the underlying disease.
Odynophagia
Weight loss due to decreased food intake.
Candida vulvovaginitis:
Symptoms of [[vulvovaginitis]] caused by [[Candida]] [[species]] are indistinguishable and include the following:<ref name="pmid97946642">{{cite journal| author=Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK| title=Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. | journal=Obstet Gynecol | year= 1998 | volume= 92 | issue= 5 | pages= 757-65 | pmid=9794664 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9794664 }}</ref><ref name="pmid16990387">{{cite journal |vauthors=Eckert LO |title=Clinical practice. Acute vulvovaginitis |journal=N. Engl. J. Med. |volume=355 |issue=12 |pages=1244–52 |year=2006 |pmid=16990387 |doi=10.1056/NEJMcp053720 |url=}}</ref><ref name="pmid9500475">{{cite journal |vauthors=Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR |title=Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations |journal=Am. J. Obstet. Gynecol. |volume=178 |issue=2 |pages=203–11 |year=1998 |pmid=9500475 |doi= |url=}}</ref>
*[[Pruritus]] is the most significant symptom
*Change in the amount and the color of [[vaginal discharge]]: It is characterized by a thick, white "cottage cheese-like" vaginal discharge
*Pain on urination ([[dysuria]])
*Pain on sexual intercourse (dyspareunia)
*[[Vulvovaginal]] soreness
*Symptoms aggravate a week before the menses.
Chronic mucocutaneous candidiasis (CMCC): (9)
CMCC is a syndrome characterized by chronic or recurrent superficial candida infection in the skin and mucous membranes in association with endocrinal and autoimmune deficiencies. (10)
Characterized by inability of T cells to react to candidal antigens.
Presents with:
Recurrent or chronic candidal infections.
Infection is usually superficial though invasive candidiasis is encountered especially in new born.(11)
Enocrinopathies as hypoparathyroidism and adrenal insufficiency may accompany chronic candidiasis.
Invasive candidiasis:
 
Candidaemia: (12)
mimics the presentation of sepsis:
*[[Fever]]: in patient who is known immunodeficient, fevers are usually high and spiking.
*A [[capillary leak syndrome]] can develop with severe [[swelling]], [[edema]], and third spacing of fluids.
*General [[symptoms]] can include flu like symptoms as well as shaking chills or [[rigors]].(13)
*If the [[respiratory system]] is the primary source for sepsis then [[sore throat]], productive [[cough]], and [[pleuritic chest pain]] may be present.
Candida osteoarticular disease:
invasion of bones usually presents after weks to months after candidaemia.
Fever is not present in all patients
Loss of function, pain and tenderness are the main presenting symptoms.
Candida endophthalmitis:
Candida endophthalmitis presents in severly immunocompromised patients but most common risk factor is IV drug abuse.
Fever: is not present consistently in all patients except associated candiaemia is present.
Red eye.
Floaters and decreased visual acuity: but markedly decreased vision is not present till very late in the course of the disease.
Eye pain
 
==References==

Latest revision as of 20:41, 2 May 2017

Historical prespective

B. Lagenbeck in 1839 in Germany was the first to demonstrate that a yeast-like fungus existed in the human oral infection "thrush." He also found that a fungus was able to cause thrush.[1]

The genera Candida, species albicans was described by botanist Christine Marie Berkhout. She described the fungus in her doctoral thesis, at the University of Utrecht in 1923. Over the years the classification of the genera and species has evolved. Obsolete names for this genus include Mycotorula and Torulopsis. The species has also been known in the past as Monilia albicans and Oidium albicans. The current classification is nomen conservandum, which means the name is authorized for use by the International Botanical Congress (IBC).

The full current taxonomic classification is available at Candida albicans.

The genus Candida includes about 150 different species. However, only a few of those are known to cause human infections. C. albicans is the most significant pathogenic (=disease-causing) species. Other Candida species causing diseases in humans include C. tropicalis, C. glabrata, C. krusei, C. parapsilosis, C. dubliniensis, and C. lusitaniae.


Classification:[2]

Candidiasis can be classified according to the site of infection into:

Localoized mucocutaneous:

  • Oropharyngeal candidiasis
  • Esophageal candidiasis
  • Candida vulvovaginitis
  • Chronic mucocutaneous candidiasis.

Invasive Candidiasis:

More serious and usually presenting in an immunocompromised host.

  • Candidaemia
  • Candida endophthalmitis
  • Candida endocarditis
  • Candida osteoarticular disease

Pathophysiology:

Candida is a normal commensal of skin and mucous membranes. A competent immune system and an intact regenerating healthy skin prevent the virulence of Candida.

The main virulence factors that mediate the infection: (2)

  1. Secreting molecules that mediate adherence into host cells
  2. Production of hydrolases which has a lytic effect on tissues and facilitate the invasion by the bacteria.
  3. Polymorphism: Candida has the ability to grow either as pseudohyphae (elongated elipsoid form) or in a yeast form (rounded to oval budding form. While the role of #polymorphism is not clearly understood in the virulence of Candida, it’s noted that species capable of producing the most severe form of the disease has this ability.
  4. Biofilm production: which means the ability to form a thick layer of the organism on the mucosal surfaces or even on catheters and dentures.

Patients was candida vulvovaginitis were found to have decreased levels of mannose binding lectins (MBL) . Further investigations revealed that 2 genetic mutations in genes responsible for MBL and IL4 production increase the host susceotibility of getting recurrent candidal vulvovaginitis.(3)

Risk factors:

Any condition that compromises cell mediated immunity, worsens the general status of the patient or provide a favorable medium for candida to form biofilms put the patient at increased risk for having candidiasis.(4)

Conditions that compromises cell mediated immunity:

  • T cell deficiencies as in DiGeorge syndrome, Wiscot-Aldrich syndrome and ataxia-telengictasia.
  • Bone marrow transplant
  • Leukaemias
  • Corticosteroids use or immunosuppresive drugs.

Conditions that worsens the general condition:

  • Malignancies
  • Recent chemotherapy
  • Trauma
  • Recent surgery
  • Prolonged hospitalization
  • Broad spectrum antibiotics
  • Renal failure
  • Haemodialysis (especially if prolonged)

Dentures that provide a favorable media for forming biofilms:

  • Prolonged central venous catheters insertion
  • Prolonged foley’s catheter insertion
  • Prolonged mechanical ventilation

Clinical manifaestations:

Oropharyngeal candidiasis:(5), (6)

Many cases are asymptomatic (mild disease or poor general condition) Dysphagia or odynphagia Difficulty tasting food feeling of mouth fullness and discomfort

Candida esophagitis:(7)

Candida esophagitis usually comes late in the course of AIDS (or any immunodeficiency) (8), so patient has the symptoms and signs of the underlying disease. Odynophagia Weight loss due to decreased food intake.

Candida vulvovaginitis:

Symptoms of vulvovaginitis caused by Candida species are indistinguishable and include the following:[3][4][5]

  • Pruritus is the most significant symptom
  • Change in the amount and the color of vaginal discharge: It is characterized by a thick, white "cottage cheese-like" vaginal discharge
  • Pain on urination (dysuria)
  • Pain on sexual intercourse (dyspareunia)
  • Vulvovaginal soreness
  • Symptoms aggravate a week before the menses.

Chronic mucocutaneous candidiasis (CMCC): (9)

CMCC is a syndrome characterized by chronic or recurrent superficial candida infection in the skin and mucous membranes in association with endocrinal and autoimmune deficiencies. (10) Characterized by inability of T cells to react to candidal antigens. Presents with: Recurrent or chronic candidal infections. Infection is usually superficial though invasive candidiasis is encountered especially in new born.(11) Enocrinopathies as hypoparathyroidism and adrenal insufficiency may accompany chronic candidiasis.

Invasive candidiasis:

Candidaemia: (12) mimics the presentation of sepsis:

Candida osteoarticular disease: invasion of bones usually presents after weks to months after candidaemia. Fever is not present in all patients Loss of function, pain and tenderness are the main presenting symptoms.

Candida endophthalmitis: Candida endophthalmitis presents in severly immunocompromised patients but most common risk factor is IV drug abuse.

Fever: is not present consistently in all patients except associated candiaemia is present. Red eye. Floaters and decreased visual acuity: but markedly decreased vision is not present till very late in the course of the disease. Eye pain

References

  1. Barnett JA (2008). "A history of research on yeasts 12: medical yeasts part 1, Candida albicans". Yeast. 25 (6): 385–417. doi:10.1002/yea.1595. PMID 18509848.
  2. "Candidiasis | Types of Diseses | Fungal Diseases | CDC".
  3. Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK (1998). "Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm". Obstet Gynecol. 92 (5): 757–65. PMID 9794664.
  4. Eckert LO (2006). "Clinical practice. Acute vulvovaginitis". N. Engl. J. Med. 355 (12): 1244–52. doi:10.1056/NEJMcp053720. PMID 16990387.
  5. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR (1998). "Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations". Am. J. Obstet. Gynecol. 178 (2): 203–11. PMID 9500475.